15:20 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Pancreatitis Mouse studies suggest PIEZO1 inhibition could help treat pancreatitis. In a mouse model of pressure-induced acute pancreatitis, pancreatic acinar cell-specific knockout of PIEZO1 or the PIEZO1 inhibitor AT-300 decreased histological disease scores and levels...
15:45 , Mar 28, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs A SNP on MPO could help predict the risk of colorectal cancer and predict survival in patients. Genotyping of 1,277 colorectal cancer patients and 1,175 unaffected individuals from the Chinese population identified an association...
18:08 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Colitis Patient sample and mouse studies suggest inhibiting DPP-4 could help treat colitis. In a mouse model of colitis, intracolonic administration of a peptide inhibitor of DPP-4 decreased macroscopic colon damage and ulcer scores, colonic...
15:56 , Apr 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Mouse studies suggest the cucurbitane analog mogroside IIIE and other TLR4 inhibitors could help treat pulmonary fibrosis. In primary lung fibroblasts from a mouse model of the disease, mogroside IIIE decreased fibroblast activation...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-6 (IL-6); tumor necrosis factor α (TNFα)

Infectious disease INDICATION: Sepsis Cell culture and mouse studies identified indole-2-carboxamide-based compounds that could help treat sepsis. Chemical synthesis and testing in lipopolysaccharide (LPS)-stimulated mouse macrophages of indole-2-carboxamide analogs identified two compounds that inhibited IL-6 secretion with...
08:00 , Feb 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: N-acylethanolamine acid amidase (NAAA; ASAHL)

Autoimmune disease INDICATION: Arthritis Rat studies suggest inhibiting NAAA could help treat arthritis. In a rat model of arthritis, an NAAA inhibitor tool compound decreased levels of NAAA in the paw, paw edema, thermal hyperalgesia and myeloperoxidase...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

GLPG1205: Development discontinued

Galapagos said it will discontinue development of GLPG 1205 to treat UC after the double-blind, international Phase IIa ORIGIN trial in about 64 patients with moderate to severe UC showed that once-daily 100 mg oral...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

GLPG1205: Completed Phase II enrollment

Galapagos completed enrollment of about 60 patients with moderate to severe UC in the double-blind, placebo-controlled, international Phase II ORIGIN trial evaluating 100 mg oral GLPG1205 once daily for 12 weeks. Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG),...
07:00 , Apr 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Myeloperoxidase (MPO)

Inflammation INDICATION: Inflammatory disease In vitro and mouse studies suggest the MPO inhibitor PF-1355 could help prevent or treat vasculitis. In human neutrophil- and blood-based assays, the 2-thiouracil-based compound PF-1355 inhibited MPO activity with EC50 values of...
07:00 , May 2, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Coronary artery disease (CAD); Parkinson's disease (PD) Myeloperoxidase (MPO) In vitro and...